The study also showed for the first time expression of SGLT-1 receptors in the heart, opening the way for clinical testing of SGLT-1/2 antagonists, such as sotagliflozin with favorable results both in diabetic [48] and non-diabetic HF patients [47]. This evidence concerns the gene SLC5A1 and hydrops fetalis.